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Background: Routine HIV pre-exposure prophylaxis (PrEP) and HIV care appointments provide opportunities
for screening men who have sex with men (MSM) for hepatitis C virus infection (HCV). However, levels of
screening required for achieving the WHO elimination target of reducing HCV incidence by 90% by 2030
among all MSM are unknown.
Methods: An HCV/HIV transmission model was calibrated to UK prevalence of HIV among MSM (4¢7%) and
chronic HCV infection among HIV-positive MSM (9¢9%) and HIV-negative MSM (1.2%). Assuming 12¢5% cover-
age of PrEP among HIV-negative MSM, we evaluated the relative reduction in overall HCV incidence by 2030
(compared to 2018 levels) of HCV screening every 12/6-months (alongside completing direct acting antiviral
treatment within 6-months of diagnosis) in PrEP users and/or HIV-diagnosed MSM. We estimated the addi-
tional screening required among HIV-negative non-PrEP users to reduce overall incidence by 90% by 2030.
The effect of 50% reduction in condom use among PrEP users (risk compensation) was estimated.
Results: Screening and treating PrEP users for HCV every 12 or 6-months decreases HCV incidence by 67¢3%
(uncertainty range 52¢779¢2%) or 70¢2% (57¢180¢8%), respectively, increasing to 75¢4% (59¢088¢6%) or
78¢8% (63¢990¢4%) if HIV-diagnosed MSM are also screened at same frequencies. Risk compensation reduces
these latter projections by <10%. To reduce HCV incidence by 90% by 2030 without risk compensation, HIV-
negative non-PrEP users require screening every 5¢6 (3¢89¢2) years if MSM on PrEP and HIV-diagnosed
MSM are screened every 6-months, shortening to 4¢4 (3¢16¢6) years with risk compensation. For 25¢0%
PrEP coverage, the HCV elimination target can be reached without screening HIV-negative MSM not on PrEP,
irrespective of risk compensation.
Interpretation: At low PrEP coverage, increased screening of all MSM is required to achieve the WHO HCV-
elimination targets for MSM in the UK, whereas at higher PrEP coverage this is possible through just screen-
ing HIV-diagnosed MSM and PrEP users.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Globally, men who have sex with men (MSM) experience a high
burden of HIV [1], with elevated levels of hepatitis C (HCV) co-infection
occurring among HIV-positive MSM in high-income countries [2], but
much lower transmission occurring among HIV-negative MSM [2,3].
This recent MSM HCV epidemic has been associated with sexual and
drug-related behaviours [4], with the polarised pattern of HCV in HIV-
infected MSM likely due to heterogeneity in risk behaviours and HIV
sero-adaptive behaviours [5]. Over 20122017, HIV incidence has
halved in the UK [6] mainly due to the UK achieving very high levels of
antiretroviral therapy (ART) coverage and HIV viral suppression [6].
Research in context
Evidence before this study
Recent modelling studies based on HIV-positive MSM in Eng-
land, Switzerland and Berlin indicate that rapid access and scale
up of HCV DAAs could lead to significant reductions in HCV inci-
dence; but that behavioural change would be required to reach
the HCV elimination targets. Similar modelling based on Victo-
ria, Australia projected that treatment within 6 months of HCV
diagnosis lowered HCV prevalence by 80% in just over 2 years,
with a similar study based in France finding that treating 70% of
those currently diagnosed every year resulted in an 80% reduc-
tion in HCV prevalence over 10 years. However, another study
highlighted the potential drawbacks of treatment as prevention
for HCV in MSM due to high re-infection rates, and so raised
concerns about attaining the 2030 elimination targets.
Added value of this study
Our study is an important addition to this literature because it is the
first to examine HCV elimination targets for the entire population
of MSM, not just HIV-positive MSM. We also consider how HCV
screening and treatment needs to evolve with the scale-up of PrEP,
and should incorporate the possible effect of risk compensation on
HCV elimination targets. These additions are useful for policy-mak-
ers working towards the WHO 2030 HCV elimination targets of
reducing HCV incidence by 90% among MSM. Importantly, at low
PrEP coverage our modelling suggests it will be difficult to reach
these elimination targets among MSM without also including
screening and treatment interventions for HIV-negative MSM, with
frequent screening of MSM on PrEP being an important addition to
ongoing HCVmanagement strategies. However, at higher PrEP cov-
erage, the elimination targets may be possible through just improv-
ing HCV screening in HIV-diagnosedMSM andMSM on PrEP.
Implications of all the available evidence
Our work supports the current literature, showing that the
2030 HCV elimination targets for incidence are achievable
among MSM. However, this target may require increased HCV
screening of all MSM with faster linkage of diagnosed individu-
als to HCV treatment. Elimination efforts that are currently only
focussing on HIV-diagnosed MSM need to expand their scope
to include other MSM groups.
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medication, which has high efficacy for preventing HIV acquisition [7,8].
Many countries are expanding the availability of PrEP among MSM [11].
However, as occurred with the expansion of ART [9], there are concerns
that PrEP use could result in increased sexual risk taking, thus increasing
the transmission of sexually transmitted infections (STIs), including HCV
[7]. Recent studies have confirmed this, giving a consistent picture that
the incidence of STIs increases following initiation of PrEP [10,11].
Although PrEP is freely available in Wales and Scotland [12], it has
limited availability in England, with PrEP being restricted to individu-
als enrolled in the IMPACT trial [13]. In all these settings, PrEP is only
available to individuals meeting specific eligibility criteria. In England,
this mainly involves reporting on-going condomless sex or other fac-
tors posing similar HIV-risk [13]. The full IMPACT trial eligibility crite-
ria is included in the Supplementary material, with there being similar
eligibility criteria in Scotland andWales [12].
The World Health organisation (WHO) recently developed a
Global Health Strategy to eliminate HCV, aiming to reduce HCV inci-
dence by 90% by 2030 [14]. Elimination initiatives are attempting toPlease cite this article as: L. Macgregor et al., Scaling up screening and tre
men in the era of HIV pre-exposure prophylaxis, EClinicalMedicine (2019achieve this goal among MSM, mainly targeting HIV-diagnosed MSM
[1517]. In the UK, HIV-diagnosed MSM are advised to be screened
for HCV each year [18], while HIV-negative MSM are rarely tested
[19] and there are no HCV testing guidelines for MSM using PrEP.
Previous modelling has considered what is required to eliminate
HCV among HIV-diagnosed MSM [20,21], but none have accounted
for the HCV transmission dynamics among HIV-negative MSM. In
this study, we use modelling to determine what HCV testing and
treatment strategies are needed to reduce the overall incidence of
HCV among MSM by 90% by 2030 in the UK. We assess how PrEP and
any associated changes in condom use may affect the impact
achieved, and determine the need for HCV screening among PrEP
users and other HIV-negative MSM to help inform future policy and
guidelines.
2. Methods
2.1. Model derivation
We adapt a previous model of HIV and HCV transmission among
MSM [5] to include PrEP use (details in Supplementary material). The
model (Supplementary Fig. S1) stratifies MSM by: HIV and PrEP status
(susceptible on/off PrEP, acute HIV infection on/off PrEP, undiagnosed
or diagnosed chronic HIV infection); HCV-status (susceptible, acute
HCV infection, undiagnosed and diagnosed chronic HCV infection);
and either low- or high-risk sexual behaviour, defined by the annual
number of anal sex partners (high-risk defined as  15). Individuals
are not assumed to change their risk.
Individuals enter the model susceptible to HIV and HCV, not using
PrEP, and either low- or high-risk. HIV and HCV transmission occurs
at rates related to an individuals’ sexual risk and prevalence of HIV
and HCV among their sexual partners. HCV infectivity is elevated for
HIV-HCV co-infected individuals based on evidence for vertical HCV
transmission (details in Supplementary materials) [22]. MSM also
mix preferentially, more commonly choosing partners of the same
sexual risk and HIV-status (see Supplementary materials).
Depending on the PrEP scenario being modelled, HIV-negative
individuals may initiate using PrEP, which confers protection to
acquiring HIV [7,8,23]. PrEP was assumed to scale-up from 2018,
with the coverage of PrEP reaching 12¢5% of HIV-negative MSM by
2020 with the average duration on PrEP being 8¢2 months [24]. PrEP
users are screened quarterly for HIV and upon a positive diagnosis
stop using PrEP. This frequent HIV-testing means PrEP users are diag-
nosed before reaching chronic HIV infection [25]. Non-PrEP users
who acquire acute HIV infection, firstly transition to undiagnosed
HIV infection and are then diagnosed at current UK HIV-testing rates
(2¢3 years between infection and diagnosis) [26]. Acute HIV is
assumed to have elevated HIV transmission risk (26-fold) [27]. A pro-
portion of HIV-diagnosed MSM are on ART, which increases survival
3¢4-fold, with a proportion being virally supressed and having negli-
gible HIV transmission risk (see Supplementary materials).
Newly HCV-infected individuals develop acute HCV infection, fol-
lowing which they either develop chronic HCV infection or spontane-
ously clear their infection and become susceptible again. The baseline
model assumes HIV-negative MSM are diagnosed for HCV based upon
symptomatic presentation after 515 years. Conversely, undiagnosed
HIV-positive MSM receive testing for HCV following HIV diagnosis,
with 88% of HIV-diagnosed MSM being screened annually in the UK
[28]. At baseline, we assume 2.2 years from diagnosis to completing
HCV treatment, consistent with UK data for pre-DAA treatments [28].
Before 2015, we assume different cure rates for HIV-positive (sus-
tained viral response or SVR of 3542%) [29] and HIV-negative MSM
(SVR of 5969%) [30] based on pre-DAA treatments, but then assume
higher cure rates from 2015 for DAA therapies (SVR of 90100%) [28].
From 2018, we then consider the impact of various scenarios of
improved HCV screening with faster linkage-to-treatment followingatment for elimination of hepatitis C among men who have sex with
), https://doi.org/10.1016/j.eclinm.2019.11.010
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current treatment rates [17]. This assumes a 3-month waiting time
and an HCV treatment duration of 812 weeks. MSM failing treatment
are retreated at the same rate as initial HCV treatment.
2.2. Parameterization of sexual risk behaviour
Sexual risk behaviours were parameterized using data from the UK
component of the European MSM Internet Survey (EMIS-UK);[5,31]
EMIS was a pan-European internet survey on interventions, needs,
behaviours and morbidities regarding HIV and STI transmission among
MSM. Individuals could complete the survey online during Summer
2010. Over 180,000 men took part from 38 countries, including 18,000
in the UK [31]. From EMIS, we calculated the level of preferential mix-
ing by HIV-status; proportion of MSM in the low and high-risk groups;
prevalence of chem-sex; and levels of condom use stratified by the
assumed HIV sero-concordancy. These model parameters are detailed
in Supplementary Table S3, and summarised in Table 1. Briefly, EMIS
data suggests 17¢4% of MSM are high-risk, amongst whom the preva-
lence of chem-sex in last year is higher than among low-risk MSM
(22.6% versus 11.5%). The baseline model assumed that MSM have sex
more often with others of the same perceived HIV-status, with per-
ceived HIV-positive concordant partnerships having lower condom
use (13%) than other partnerships (68%) [5].
2.3. Baseline model calibration
Assuming historic levels of HCV screening and pre-DAA SVR rates
with no PrEP, the model was firstly calibrated to give a stable HIV
and HCV epidemic in 2012, in line with prevalence data from the UK
Collaborative HIV Cohort (UK CHIC) study [28]. UK CHIC involved a
collaboration of UK centres providing care for people living with HIV
(PLHIV). The study gathered data relating to clinical care of PLHIV
since 1996, including data on HCV incidence and prevalence among
HIV-diagnosed MSM.
To calibrate the model, we firstly randomly sampled parameter
sets from their uncertainty ranges in Table S3. We then used non-lin-
ear least-squares fitting (see Supplementary) to estimate transmis-
sion parameters for HIV and HCV that result in each model run giving
an overall HIV prevalence within the range 4¢35¢3% [32] and a
chronic HCV prevalence within the range 9¢610¢2% for HIV-infected
MSM at equilibrium [28]. Model runs were only accepted if they also
projected a prevalence of HCV among HIV-negative MSM within the
range of 0¢62¢1% [34]. In total, we performed 668 runs to obtain 500
fits (75% acceptance rate). For our results, we present the 2¢5% to
97¢5% percentile range from these 500 model fits, denoted as the 95%
central range (95% CR).
For each model fit, we then assume that over 20122017 there is
an increase in: (1) proportion of HIV-diagnosed MSM on ART from 85%
[32] to 98% [6]; (2) proportion of those on ART that are virally sup-
pressed from 72% to 97%; and (3) HIV testing frequency from every 3¢2
years [33] to 2¢3 years [26]. The resulting model projections (Supple-
mentary Figs. S7S12) were then validated against data suggesting a
55¢5% (95% CI 34¢472¢7%) decrease in the annual rate of new HIV
infections among MSM over 20122017 in the UK [6]. HCV prevalence
and incidence also decrease over this period due to an increase to DAA
SVR rates from 2015 [35,36]. Despite being not fit to this data, our
model projections for HCV incidence among HIV-diagnosed MSM and
HIV-negative MSM off PrEP for 2012 are comparable to UK data esti-
mates from that period, as shown in Supplementary Figs. S7S12 [37].
2.4. PrEP intervention scenarios
The calibrated model was used to estimate the impact of initiating
a PrEP programme, with the coverage of PrEP scaling-up to 12¢5% of
HIV-negative MSM over the period 20182020 while assuming the
Please cite this article as: L. Macgregor et al., Scaling up screening and tre
men in the era of HIV pre-exposure prophylaxis, EClinicalMedicine (2019average duration on PrEP was 8.2 months [24]. This coverage
assumption was based on NHS-eligibility criteria, where only MSM
recently participating in unprotected sex are eligible for PrEP. The rel-
ative coverage of PrEP among low- and high-risk MSM reflects this
eligibility criteria (see Supplementary materials). The efficacy of PrEP
for reducing the risk of HIV acquisition was assumed to be 91.5%
(8697%) [7,8,23].
PrEP driven risk compensation was also modelled. However,
because of inconclusive data on how sexual behaviours may change
[7,8,23,38], we only considered reductions in condom use among
MSM using PrEP. In our modelling, we either assume no risk compen-
sation (Scenario S0) or that all PrEP users halve their consistency of
condom use from 68% to 34% with all partners (Scenario S1). This
assumption is varied in our sensitivity analyses.2.5. Model analyses
The main aim of the analysis is to determine what level of HCV
screening and treatment is needed among different MSM sub-popu-
lations to eliminate HCV in all MSM, while incorporating the possible
effects of PrEP scale-up. However, we firstly considered the possible
impact of using DAAs as the new standard of care from 2015, and the
effect that PrEP alone could have on the number of new HIV and HCV
infections, as well as HCV prevalence and incidence in 2030 com-
pared to 2018 levels.
We then evaluated the impact of different HCV screening and
treatment scenarios initiated from 2020, to see what is needed to
achieve the WHO elimination target. We firstly evaluated the impact
of more frequent HCV screening for HIV-diagnosed MSM or PrEP
users, with PrEP users otherwise having the same low level of HCV
screening as HIV-negative MSM. The impact on HCV incidence among
MSM using PrEP was estimated, with the relative change being com-
pared to what the incidence was in those MSM in 2018. Similarly, the
impact on HCV incidence in other groups was estimated. For these
scenarios, we also assumed improved linkage-to-treatment for those
MSM sub-groups with enhanced screening, with MSM completing
treatment within 6 months of diagnosis. Lastly, we considered
whether improved screening and linkage-to-treatment for HIV-nega-
tive MSM not using PrEP was needed to reach the elimination targets.
For MSM using PrEP and HIV-diagnosed MSM, 3, 6 or 12-monthly
screening were considered, while the screening frequency for HIV-
negative MSM not using PrEP was fitted to give an overall 90% reduc-
tion in HCV incidence by 2030.2.6. Uncertainty analysis
To ascertain which parameters are important for determining
variability in the impact projections across the 500 baseline model
fits, a linear regression analysis of covariance (ANCOVA) was per-
formed on the projected decrease in overall HCV incidence
(20182030) of undertaking 6-monthly screening among HIV-diag-
nosed MSM and MSM using PrEP (no risk compensation). The pro-
portion of the sum of squares contributed by each parameter was
calculated to determine each parameters’ importance to the vari-
ability in our projections.
We also performed a series of sensitivity analyses where we var-
ied the following: (1) 4 versus 6 months between HCV diagnosis and
treatment completion; (2) 25% versus 12¢5% coverage of PrEP; (3)
condom use among PrEP users decreases to 13% instead of 34% with
risk compensation; (4) PrEP is distributed evenly between high and
low-risk MSM, or to (5) just low-risk MSM or (6) just high-risk MSM;
(7) no increased infectiousness of HCV with HIV co-infection; (8) 50%
less mixing by HIV-status following PrEP introduction; (9) no
increased risk associated with chem-sex; (10) HCV transmission rate
decreased by 20% from 2012 to simulate a decreasing HCV epidemicatment for elimination of hepatitis C among men who have sex with
), https://doi.org/10.1016/j.eclinm.2019.11.010
Table 1
Key model parameters with ranges and details of estimation included. (For the full version see Supplementary Table S3.)
Model parameters Value and uncertainty range References Comment
HCV related parameters
Efficacy of HCV treatment with DAAs after 2015 95% (90100%) [35,36] Efficacy is the sustained viral response
Duration of HCV treatment in years 0.19 (0.150.23) [15] Duration of DAA treatment generally 8 to 12
weeks
Rate of HCV screening in HIV-diagnosed MSM at
baseline
1.13 person-years [28] 88% of HIV-diagnosed MSM are HCV tested each
year during routine HIV check-up appoint-
ments from UK-CHIC data
Rate of HCV screening in HIV-negative MSM at
baseline
0.10 (0.070.20) person-years [44] HIV-negative MSM not normally diagnosed with
HCV until have symptoms unless they are high-
risk, so assume 515 years
Average delay from HCV diagnosis to initiation of
treatment.
2.2 years [28] UK-CHIC data for HIV-diagnosed MSM and
assume same for other MSM
Behavioural parameters
Proportion of MSM that are low-risk 0.83 (0.790.86) EMIS Proportion of MSMwith <15 anal sex
partners in the last year.
Proportion of MSM that are high-risk 0.17 (0.210.14) EMIS Proportion of MSMwith  15 anal sex
partners in the last year.
Annual number of anal sex partners in the last
year in the low-risk group
2.9 (2.33.5) EMIS Average number of anal sex partners among low-
risk MSM with a +/ 20%. uncertainty range.
Annual number of anal sex partners in the last
year in the high-risk group
29.1 (23.334.9) EMIS Average number of anal sex partners among
high-risk MSMwith a +/ 20%. uncertainty
range.
Relative risk of HIV acquisition among high-riskMSM
compared to low-riskMSM
1.3 (1.11.5) EMIS and [45] EMIS data on prevalence of chem-sex in last year
for low and high risk MSM combined with esti-
mated increased risk of HIV acquisition due to
chem sex in MSM studies. Relative risk is dif-
ference between low and high risk MSM [47].
Relative risk of HCV acquisition among high-risk
MSM compared to low-risk MSM
1.5 (1.11.9) EMIS and [46] EMIS data on prevalence of chem-sex in last year
for low and high risk MSM combined with esti-
mated increased risk of HCV acquisition due to
chem sex in MSM studies. Relative risk is dif-
ference between low and high risk MSM [47].
The proportion of MSMwho mix like with like by
HIV-status
0.35 (0.280.42) EMIS EMIS data on proportion of partnerships
chosen between people of the same HIV-status
assuming no errors in judgement.
Probability of error in serosorting judgement
(randommixing otherwise)
24.9% (12.145.7%) EMIS EMIS data on proportion of individuals who make
assumptions about partner’s HIV-status based
on unreliable reasons
Probability of condom usage between HIV
diagnosed MSM and a partner assumed to be
HIV-positive
13.0% (10.415.6%) EMIS EMIS data on condom use with last casual partner
when both sides of partnership are thought to
be HIV-positive. Assume range +/ 20% either
side.
Probability of condom usage in other MSM
partnerships (not ones thought to be both
HIV-positive)
68.0% (54.481.6%) EMIS EMIS data on condom use with last casual partner
when partnerships not thought to be sero-con-
cordant. Assume range +/ 20% either side.
Efficacy of condoms per sex act 0.91 (0.691.00) [48] Per act protection provided by condom use dur-
ing anal sex
Proportion of MSMwho mix like with like by risk
status
0.25 (0.000.50) EMIS EMIS data on whether individuals in each risk
group meet their partners in the same places.
Assume large uncertainty.
PrEP related parameters
Proportion of MSM taking up PrEP by 2020 12.5% or 25.0% EMIS [25] 12.5% coverage estimated from EMIS data using
basic element of eligibility criteria from NHS
England  recent condomless sex. Higher value
assumed to encompass uncertainty.
Relative increase in coverage of PrEP in high-risk
MSM versus low-risk MSM
2.6 (2.42.8) EMIS [25] EMIS data applied to NHS England eligibility cri-
teria for low and high-risk MSM
Efficacy of PrEP in reducing HIV incidence 91.5% (86.097.0%) [8,49] Range in efficacy from UK PROUD study [8] and
real-world study of PrEP use among MSM in
France and Canada [49].
Rate of HIV testing for PrEP users Every 3 months [13] Standard of care for HIV testing in PrEP users in
UK
Rate of HCV testing for PrEP users Every 312 months; baseline same
as HIV-negative MSM
Varied in different model scenarios
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Table 2
Model projections of the impact of PrEP on HCV prevalence, incidence and the relative change in new HIV and HCV infections for 12¢5% and 25¢0% PrEP coverage with and without
risk compensation. The risk compensation scenario assumes condom use among PrEP users reduces from 68% to 34%. *PrEP users in ‘No PrEP’ scenario are assumed to be representa-
tive of MSMwho are eligible for PrEP in 2018.
PrEP scenario Relative change (%) in
new infections from
2018 to 2030 compared
to no PrEP scenario
HCV prevalence by 2030 HCV Incidence by 2030 (per 100 person-years)
HIV HCV All MSM HIV
positive
On PrEP* HIV
negative
not on PrEP
All
MSM
HIV positive On PrEP* HIV
negative
not on PrEP
No PrEP 0.0% 0.0% 1.2% 2.6% 2.8% 1.2% 0.10 0.64 0.29 0.10
12¢5% coverage of PrEP
Scenario S0  no risk
compensation
44.7% 1.0% 1.2% 2.3% 2.1% 1.0% 0.10 0.58 0.17 0.09
Scenario S1  condom use in
PrEP users falls from 68%
to 34%
40.5% 42.5% 1.5% 2.9% 3.0% 1.2% 0.17 0.81 0.39 0.13
25¢0% coverage of PrEP
Scenario S0  no risk
compensation
67.3% 1.6% 1.2% 2.2% 2.1% 0.8% 0.10 0.56 0.17 0.07
Scenario S1  condom use in
PrEP users falls from 68%
to 34%
63.1% 80.7% 1.8% 3.3% 3.3% 1.2% 0.23 0.99 0.47 0.15
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increased by 20% to simulate an increasing HCV epidemic.
3. Results
3.1. Impact of PrEP on HIV
A 12¢5% coverage of PrEP among HIV-negative MSM translates to
27¢6% of high-risk HIV-negative MSM and 10¢3% of low-risk HIV-neg-
ative MSM receiving PrEP. Over 20182030, this PrEP coverage
results in 44¢7% (95%CR 30¢466¢7%) of new HIV infections being pre-
vented if sexual behaviours remain unchanged (scenario S0) as
shown in Table 2. This large impact on HIV is due to PrEP being tar-
geted to high-risk MSM resulting in the basic reproductive rateFig. 1. Projections of HCV (A) prevalence and (B) incidence among different subgroups of MS
with and without risk compensation. The projections assume 12¢5% coverage of PrEP in H
assumes condom use among PrEP users reduces from 68% to 34%. Point estimates are the med
from our 500 model fits. *PrEP users at baseline are assumed to be representative of MSMwh
Please cite this article as: L. Macgregor et al., Scaling up screening and tre
men in the era of HIV pre-exposure prophylaxis, EClinicalMedicine (2019decreasing close to one. Less HIV-impact is achieved if PrEP is not tar-
geted to high-risk MSM (Fig. S5).
3.2. Impact of PrEP on HCV
Due to switching to DAA therapies from 2015, HCV incidence will
decrease by 42.1% (95%CR 20¢8%61¢9%) over 20182030, even with-
out the introduction of PrEP or enhanced HCV screening, and overall
HCV prevalence will decrease by 32.6% (95%CR 20.5-44.4%) due mainly
to a 62.2% (95%CR 50.8-71.2%) decrease in HCV prevalence in HIV-diag-
nosed MSM.With 12¢5% coverage of PrEP, an additional small decrease
in HCV incidence occurs (by 45¢1% (95%CR 16¢867¢2%)  Fig. 1 and
Table 2) if sexual behaviours remain unchanged (S0) and HCV screen-
ing remains the same. This decrease is due to PrEP reducing theM by 2030 for the baseline ‘no PrEP’ scenario and due to the introduction of PrEP both
IV-negative MSM and no additional HCV screening. The risk compensation scenario
ian of our model projections with the whiskers representing the 2¢5 to 97¢5 percentiles
o are eligible for PrEP in 2018.
atment for elimination of hepatitis C among men who have sex with
), https://doi.org/10.1016/j.eclinm.2019.11.010
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translating to less HIV/HCV co-infections. Interestingly, the HCV preva-
lence and incidence among HIV-negative MSM using PrEP are both
about 3-fold higher than other HIV-negative MSM (Fig. 1) due to many
PrEP users being high-risk (Supplementary Fig. S3). However, although
HIV-positive MSM and MSM on PrEP have the highest prevalence of
HCV, HIV-negative MSM not using PrEP on average harbour 73¢1% of
all HCV infections (Supplementary Fig. S4).
With a halving in condom use among PrEP users (S1), HCV inci-
dence now only decreases by 5¢9% (95%CR 59¢4% to 49¢5%) over
20182030.
3.3. Impact of increasing HCV screening in PrEP users
In the previous section, no additional HCV screening of PrEP users
occurred. Assuming 12¢5% coverage of PrEP and no risk compensation
(S0), screening PrEP users every 12, 6 or 3-months (and reducing time to
completing treatment to 6-months) reduces the HCV incidence among
PrEP users by 65¢7% (95%CR 51¢177¢5%), 68¢8% (95%CR 55¢979¢7%) or
70¢4% (95%CR 58¢480¢7%), respectively, all compared to 2018 levels
(Fig. 2), and the HCV incidence among all MSM decreases by 67¢3%
(95%CR 52¢779¢2%), 70¢2% (95%CR 57¢180¢8%) or 71¢8% (95%CR
59¢581¢6%) (Fig. 3). This sizeable impact is due to HCV transmission
being primarily driven by high-risk MSM, which predominate among
PrEP users, with the large impact of HCV treatment in PrEP users having
a large subsequent impact among other high-risk MSM (especially HIV-
positive MSM) due to them preferentially mixing with each other (Sup-
plementary materials). Risk compensation (S1) reduces the impact on
HCV incidence in PrEP users of screening PrEP users by about half (Fig. 2).
3.4. Screening requirements for reaching WHO HCV elimination targets
Fig. 3 shows that screening HIV-diagnosed MSM and/or PrEP users
more often (3, 6 or 12-monthly) and reducing the time to completing
treatment (6 months) can dramatically reduce the overall incidence ofFig. 2. Relative reduction in HCV (A) prevalence and (B) incidence over 2018 to 2030 comp
months and complete HCV treatment within 6 months of diagnosis. Projections are given w
dom use among PrEP users reduces from 68% to 34%. The projections with no additional scre
jections with the whiskers representing the 2¢5 to 97¢5 percentiles from our 500 model fits. *
Please cite this article as: L. Macgregor et al., Scaling up screening and tre
men in the era of HIV pre-exposure prophylaxis, EClinicalMedicine (2019HCV by 2030. For instance, without risk compensation if we improve
screening to 3-monthly in only HIV-diagnosed MSM then incidence
will decrease by 57¢1% (95%CR 27¢080¢1%) by 2030, whereas it will
decrease by 80¢4% (95%CR 66¢691¢2%) if we also undertake 3-
monthly screening in PrEP users. With risk compensation, less impact
is achieved, although this is small (10% reduction) when both PrEP
users and HIV-diagnosed MSM are screened and treated.
Although considerable impact can be achieved from screening
HIV-diagnosed MSM and PrEP users, at 12.5% PrEP coverage it is
unlikely to achieve a 90% decrease in overall incidence by 2030 unless
we also enhance HCV screening and linkage-to-treatment among
HIV-negative MSM not using PrEP. Without risk compensation,
screening HIV-negative non-PrEP users every 4¢8 (95%CR 3¢48¢0)
years will result in a 90% reduction in incidence by 2030 if PrEP users
and HIV-diagnosed MSM are screened yearly (Fig. 4). These screening
frequencies reduce if PrEP users and HIV-diagnosed MSM are
screened more frequently but increase with risk compensation.
3.5. Uncertainty analysis
Uncertainty in the increased infectiousness of HCV due to HIV
co-infection and the ratio of the number of high-risk MSM on PrEP
compared to low-risk MSM accounted for 71.8% of the overall varia-
tion in the projected impact on HCV incidence (20182030) of
undertaking 6-monthly screening among HIV-diagnosed MSM and
HIV-negative MSM on PrEP (Supplementary Tables S5 and S6). Oth-
erwise, the efficacy of condoms and the probability of condom usage
between pairings other than a HIV-diagnosed MSM and a partner
perceived to be HIV-positive accounted for 9¢0% and 7¢7% of the var-
iation, respectively.
Fig. 5 shows the effect of our sensitivity analyses, with higher cov-
erage of PrEP among HIV-negative MSM (25¢0% instead of 12¢5%)
resulting in the biggest increase in impact aside from giving PrEP to
all high-risk MSM. Indeed, in these two scenarios just screening HIV-
diagnosed MSM and MSM on PrEP can now result in HCV elimination.ared to 2018 levels among PrEP users when they are screened for HCV every 3, 6 or 12
ith and without risk compensation, with the risk compensation scenario assuming con-
ening are also shown for comparison. Point estimates are the median of our model pro-
This is compared to the prevalence of HCV in MSMwho are eligible for PrEP in 2018.
atment for elimination of hepatitis C among men who have sex with
), https://doi.org/10.1016/j.eclinm.2019.11.010
Fig. 3. Relative decrease in overall HCV incidence over 2018 to 2030 due to different HCV screening and treatment scenarios among MSM on PrEP and/or HIV-diagnosed MSM. MSM
subgroups with enhanced screening also complete HCV treatment within 6 months of diagnosis. Projections are given (A) without and (B) with risk compensation, with the risk
compensation scenario assuming condom use among PrEP users reduces from 68% to 34%. Dashed line in each figure gives change in HCV incidence by 2030 with no change in HCV
screening. Point estimates are the median of our model projections with whiskers representing the 2¢5 to 97¢5 percentile range from our 500 model fits.
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higher level of risk compensation (to 13% condom use among PrEP
users) or PrEP was equally used by low- and high-risk MSM. Other
changes in the model assumptions had a small effect, includingFig. 4. Required duration between HCV screening tests amongHIV-negativeMSMnot on PrEP (as
pared to 2018 levels. HIV-diagnosed MSM and/or MSM on PrEP are screened every 3, 6 or 12 mon
jections are given with and without risk compensation, with the risk compensation scenario assum
current frequency of HIV testing in UK. Point estimates are themedian of our model projections w
Please cite this article as: L. Macgregor et al., Scaling up screening and tre
men in the era of HIV pre-exposure prophylaxis, EClinicalMedicine (2019shorter time to HCV treatment completion after diagnosis (4 instead
of 6 months) and a 50% decrease in preferential mixing by HIV-status
after the introduction of PrEP. Importantly, none of the sensitivity
analyses resulted in the HCV screening frequency of HIV-negativesuming 12¢5% PrEP coverage) in order to reach a 90% HCV incidence reduction by 2030 com-
ths, with all MSM subgroups completing HCV treatment within 6 months of diagnosis. Pro-
ing condom use among PrEP users reduces from 68% to 34%. Dashed line shows estimated
ith whiskers representing the 2¢5 to 97¢5 percentile range from our 500model fits.
atment for elimination of hepatitis C among men who have sex with
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Fig. 5. One-way sensitivity analysis on the (A) percentage reduction in HCV incidence over 2018 to 2030, and (B) the frequency of screening needed in HIV-negative non-PrEP users
to reach an overall 90% reduction in HCV among MSM by 2030, given 6 monthly HCV screening in HIV-positive MSM and PrEP users. Scenario 0 shown for reference as point and
whisker and grey vertical line. Point and whiskers represent the median values along with the 2¢5 to 97¢5 percentiles of the model projections across the 500 baseline model fits.
*Note: the 25% PrEP coverage scenario and distribution of PrEP to only high-risk MSM is not shown in (B) because it does not require any screening in HIV-negative MSM not on
PrEP to reach an overall 90% reduction in HCV among MSM by 2030.
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HIV in this group (every 2¢3 years; shown as dashed line in Fig. 5).
4. Discussion
Our results highlight that PrEP users as well as HIV-diagnosedMSM
are important and convenient groups for targeting HCV screening and
treatment initiatives because of their higher risk and frequent health
check-ups, which are normally every 3 and 6 months, respectively
[25]. Indeed, with 12¢5% coverage of PrEP among HIV-negative MSM,
yearly HCV screening of MSM on PrEP with rapid linkage-to-treatment
could reduce the overall HCV incidence among MSM by up to 67¢3%
(95%CR 52¢779¢2%) over 2018 to 2030, with this increasing to 79¢6%
(95% CR 64¢691¢0%) if HIV-diagnosed MSM also receive equivalent
screening and treatment. However, although considerable impact is
possible from just reaching these groups, at this lower PrEP coverage
(12.5%) the WHO HCV elimination targets cannot be reached without
also improving screening (and linkage-to-treatment) among HIV-neg-
ative MSM not on PrEP to every 38 years. This changes, though, at
higher PrEP coverage (25¢0%), where only HIV-diagnosed MSM and
PrEP users will require improved screening to reach the elimination
target. Importantly, the required HCV screening frequencies in all
MSM groups for achieving elimination are less than their average fre-
quency of HIV testing in the UK [25,26], suggesting that these increases
in HCV testing should be feasible if done at the same time as existing
HIV testing using the same blood samples.
Our projections also highlight the importance of maintaining con-
dom use among PrEP users, possibly through including counselling
on STI and HCV risk for PrEP users as part of routine healthcare visits.
Otherwise, reductions in condom use among PrEP users will increase
HCV and STI transmission, especially among PrEP users and HIV-diag-
nosed MSM. Importantly, though, enhanced HCV screening in PrEP
users may offset these additional HCV risks with our modelling sug-
gesting similar impact can be achieved from our screening activities
irrespective of the level of risk compensation.
The strength of our analysis is in modelling the full epidemic of
HIV and HCV among MSM in the UK, while accounting for heteroge-
neities in sexual risk, patterns of mixing by HIV-status, and using
detailed UK data. Despite these strengths, there are limitations.
Firstly, because the model is UK-specific, it may have limited gener-
alisability to other settings. Although most developed countries have a
similar predominance of HCV in HIV-diagnosed MSM, some epidemics
were increasing or decreasing before the introduction of DAAs [3],
while it was relatively stable in the UK in 2012 [28]. Our sensitivity
analyses suggest that it will be harder to control an increasing HCV
epidemic, with a greater frequency of HCV screening being needed
among HIV-negative MSM not on PrEP to reach the elimination targets
than for a stable or decreasing HCV epidemic. Unfortunately, more pre-
cise parameterisation to specific settings is needed to form more
detailed conclusions about the impact of our interventions’ in other
settings. Additionally, our projections should not be generalised to
lower and middle-income country settings which have different pat-
terns of HIV and HCV prevalence amongMSM [2].
Secondly, to simplify our modelling we did not attempt to recre-
ate the entire historical HCV epidemic among MSM in the UK [28,33];
rather we assumed a stable HCV epidemic until 2012 (before the
introduction of DAA treatments) as approximated by data from
around that time. We also did not explicitly model the role of chem-
sex; which we simplified by assuming a factor increase in transmis-
sion risk, reflective of what is found in the literature (see Supplemen-
tary materials). MSM were also assumed to have similar risk
behaviour over their entire lifetime [39] due to insufficient data to
parameterise transitions between risk groups over time.
Lastly, uncertainty exists in the data used by themodel which prop-
agates to uncertainty in our model projections. For instance, as with all
large MSM datasets which include detailed sexual behavioural data,Please cite this article as: L. Macgregor et al., Scaling up screening and tre
men in the era of HIV pre-exposure prophylaxis, EClinicalMedicine (2019the EMIS dataset is likely to be biased towards more highly educated
and higher risk MSM due to the need to perform convenience sampling
to obtain a large number of respondents [40]. However, because EMIS
was widely distributed and undertaken by 18,000 men in UK, these
biases should be less than for much smaller surveys undertaken in gay
venues [40]. Our uncertainty analyses show themodel is most sensitive
to the increased infectiousness of HCV among HIV co-infected MSM
and the level of heterogeneity in risk in the two risk groups. Better data
on these parameters would improve our model projections. Impor-
tantly, we also cannot be certain of the exact scale-up of PrEP, nor the
level of risk compensation that may occur among PrEP users. Our
model projections suggest that uncertainty in the coverage of PrEP
could have a large effect on our findings, while encouragingly, uncer-
tainty in levels of risk compensation has little effect on the impact of
large increases in screening.
Several modelling studies have projected the impact of HCV treat-
ment among HIV-diagnosed MSM, but none have modelled the full
HCV transmission dynamics and HCV treatment elimination require-
ments for all MSM [20,21,41,42]. Our analysis builds on these previ-
ous studies by evaluating the level of HCV screening and treatment
needed in all MSM sub-groups. Our analysis is novel in considering
the effect of PrEP on HCV elimination targets, and the additional
screening opportunities this provides. Our work compliments recent
modelling from the US showing the beneficial impact that PrEP scale-
up could have on STI transmission through more frequent STI screen-
ing at routine PrEP check-ups [43].
In the era of PrEP scale-up, our modelling suggests that at low PrEP
coverage, 12, 6 or 3-monthly HCV screening of HIV-diagnosed MSM
and PrEP users, alongside less frequent screening (every 38 years) of
HIV-negative non-PrEP users, could achieve the WHO elimination tar-
get for decreasing HCV incidence by 2030 in the UK. At higher PrEP
coverage, this may be achievable with just increased screening in HIV-
diagnosed MSM and PrEP users. Importantly, these elimination targets
are not possible through only screening HIV-diagnosed MSM (as most
elimination initiatives are doing), with the scale-up of PrEP providing
a valuable opportunity for increasing HCV-screening among higher-
risk MSM. Importantly, though, this added impact of screening PrEP
users relies on the assumption that PrEP users are in regular contact
with care, which may not be the case if MSM acquire PrEP through
unofficial channels. This emphasises the importance of making PrEP
freely available through formal channels to ensure that HCV and other
STIs can be tested and treated effectively.
Lastly, our study has direct implications for the NHS-England
commitment to eliminate HCV through giving specific screening tar-
gets for achieving this goal. For other countries with similar HCV epi-
demics in MSM [3], our findings highlight the need to look beyond
just screening HIV-diagnosed MSM, to also screening PrEP users and
HIV-negative non-PrEP users.
Declaration of Competing Interest
NKM has received unrestricted research grants from Gilead, and
honoraria from Gilead. NKM has also received honorarium of Merck.
MH personal fees from MSM Gilead and Jansen. JN has recieved
research grants from Gilead Sciences Europe. PV has received unre-
stricted research grants off Gilead, and honoraria off Gilead and Abb-
vie. LM, MD, FH and PW have nothing to declare.
Partial presentation of results in meetings
N/A.
Financial support
Engineering and Physical Sciences Research Council (EPSRC) stu-
dentship for the Ph.D. studies of Louis MacGregor. This work was alsoatment for elimination of hepatitis C among men who have sex with
), https://doi.org/10.1016/j.eclinm.2019.11.010
ARTICLE IN PRESS
JID: ECLINM [m5G;December 19, 2019;9:55]
10 L. Macgregor et al. / EClinicalMedicine 00 (2019) 100217partly funded by the Health Protection Research Unit in Evaluation of
Interventions.
Acknowledgements
EMIS was funded by a grant of the European Commission under
the EU Health Programme 2008-2013, as stipulated in Grant Agree-
ment 2008 12 14 of the Executive Agency for Health and Consumers
(EAHC). Further funding was received from CEEISCat (Centre d’Estu-
dis Epidemiologics sobre les ITS/HIV/SIDA de Catalunya, Spain);
Department of Health for England; Maastricht University (The Neth-
erlands); Regione del Veneto (Italy); and Robert Koch Institute (Ger-
many). Further funding was provided by: German Ministry of Health
for the participation of men living in Ukraine and Moldova; Finnish
Ministry of Health for Finland; Norwegian Institute of Public Health
for Norway; Swedish Board of Health and Welfare for Sweden; and
Bundeszentrale f€ur gesundheitliche Aufkl€arung (BzGA) for German
resident men.
MH and PV would also like to acknowledge support from the
NIHR funded Health Protection Research Unit in Evaluation of Inter-
ventions. PV would also like to acknowledge the NIHR funded Health
Protection Research Unit in STIs and BBVs. NM was supported by the
National Institute for Drug Abuse [grant number R01 DA037773] and
the University of California San Diego Center for AIDS Research
(CFAR), a National Institute of Health (NIH) funded program [grant
number P30 AI036214].
Supplementary materials
Supplementary material associated with this article can be found
in the online version at doi:10.1016/j.eclinm.2019.11.010.
References
[1] Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in
men who have sex with men. Lancet 2012;380(9839):367–77.
[2] Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection
in people living with HIV: a global systematic review and meta-analysis. Lancet
Infect Dis 2016;16(7):797–808.
[3] Ghisla V, Scherrer AU, Nicca D, Braun DL, Fehr JS. Incidence of hepatitis C in HIV
positive and negative men who have sex with men 20002016: a systematic
review and meta-analysis. Infection 2017;45(3):309–21.
[4] Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in
HIV-positive men who have sex with men linked to high-risk sexual behaviours.
AIDS 2007;21(8):983–91.
[5] MacGregor L, Martin NK, Mukandavire C, et al. Behavioural, not biological, factors
drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analy-
sis including HCV treatment-as-prevention impact. Int J Epidemiol 2017;46
(5):1582–92.
[6] Nash S, Desai S, Croxford S, et al. Progress towards ending the HIV epidemic in the
United Kingdom 2018 report. Public Health England; 2018.
[7] Molina JM, Capitant C, Spire B, et al. On-Demand preexposure prophylaxis in men
at high risk for HIV-1 infection. N Engl J Med 2015;373(23):2237–46.
[8] McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the
acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase
of a pragmatic open-label randomised trial. Lancet 2016;387(10013):53–60.
[9] Bezemer D, de Wolf F, Boerlijst MC, et al. A resurgent HIV-1 epidemic among men
who have sex with men in the era of potent antiretroviral therapy. AIDS 2008;22
(9):1071–7.
[10] Traeger MW, Cornelisse VJ, Asselin J, et al. Association of HIV preexposure pro-
phylaxis with incidence of sexually transmitted infections among individuals at
high risk of HIV infection. JAMA 2019;321(14):1380–90.
[11] Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for HIV infection and
new sexually transmitted infections among men who have sex with men. AIDS
2016;30(14):2251–2.
[12] Terrence Higgens Trust. I want Prep now. https://www.iwantprepnow.co.uk.
Accessed 2019.
[13] National Health Service (NHS) England. Prep impact trial. https://www.prepim-
pacttrial.org.uk. Accessed 2017.
[14] World Health Organization (WHO). Combating hepatitis B and C to Reach Elimi-
nation by 2030. 2016.
[15] National Health Service (NHS) England. Eliminating Hepatitis C in England. All-
Party Parliamentary Group on Liver Health Inquiry Report 2018.
[16] Kracht PAM, Arends JE, van Erpecum KJ, et al. Strategies for achieving viral hepati-
tis C micro-elimination in the Netherlands. Hepatol Med Policy 2018;3:12.Please cite this article as: L. Macgregor et al., Scaling up screening and tre
men in the era of HIV pre-exposure prophylaxis, EClinicalMedicine (2019[17] Boerekamps A, van den Berk GE, Lauw FN, et al. Declining hepatitis C virus (HCV)
incidence in Dutch human immunodeficiency virus-positive men who have sex
with men after unrestricted access to HCV therapy. Clin Infect Dis 2018;66
(9):1360–5.
[18] National AIDS Trust. Hepatitis C and HIV Co-Infection. https://www.nat.org.uk/
sites/default/files/publications/Jan-2012-Hepatitis-C-and-HIV-co-infection.pdf.
Accessed 2019.
[19] World Health Organization (WHO). World Health Organization: Hepatitis C Fact
Sheet. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed
2019.
[20] Martin NK, Boerekamps A, Hill AM, Rijnders BJA. Is hepatitis C virus elimination
possible among people living with HIV and what will it take to achieve it. J Int
AIDS Soc 2018;21(Suppl 2):e25062.
[21] Martin N, Jansen K, van der Heiden M, et al. Can HCV be eliminated among HIV-
infected MSM in Berlin? Modeling a setting with increasing incidence and high
treatment rates. J Hepatol 2018;68(Suppl 1):S192–3.
[22] Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepa-
titis C virus: systematic review and meta-analysis. Clin Infect Dis 2014;59
(6):765–73.
[23] Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation
in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One 2013;8(12):
e81997.
[24] Spinelli MA, Scott HM, Vittinghoff E, et al. Missed visits associated with future
preexposure prophylaxis (PrEP) discontinuation among prep users in a municipal
primary care health network. Open Forum Infect Dis 2019;6(4) ofz101.
[25] NHS England. Clinical Commissioning Policy Proposition: Pre-Exposure Prophy-
laxis (PrEP) to Prevent the Acquisition of HIV in Adults. 2016.
[26] Ong KJ, Desai S, Field N, et al. Economic evaluation of HIV pre-exposure prophy-
laxis among men-who-have-sex-with-men in England in 2016. Euro Surveill
2017;22(42).
[27] Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infec-
tion. J Infect Dis 2008;198(5):687–93.
[28] Martin NK, Thornton A, Hickman M, et al. Can hepatitis C virus (HCV) direct-act-
ing antiviral treatment as prevention reverse the HCV epidemic among men who
have sex with men in the United Kingdom? Epidemiological and modeling
insights. Clin Infect Dis 2016;62(9):1072–80.
[29] Davies A, Singh KP, Shubber Z, et al. Treatment outcomes of treatment-naive hep-
atitis C patients co-infected with HIV: a systematic review and meta-analysis of
observational cohorts. PLoS One 2013;8(2):e55373.
[30] Borroni G, Andreoletti M, Casiraghi MA, et al. Effectiveness of pegylated inter-
feron/ribavirin combination in 'real world' patients with chronic hepatitis C virus
infection. Aliment Pharmacol Ther 2008;27(9):790–7.
[31] Weatherburn P, Schmidt AJ, Hickson F, et al. The European men-who-have-sex-
with-men internet survey (EMIS): design and methods. Sexuality Research and
Social Policy 2013;10(4):243–57.
[32] Aghaizu A, Brown AE, Nardone A, et al. HIV in the United Kingdom 2013 Report.
Public Health England; 2013.
[33] Birrell PJ, Gill ON, Delpech VC, et al. HIV incidence in men who have sex with men
in England and Wales 200110: a nationwide population study. Lancet Infect Dis
2013;13(4):313–8.
[34] Price H, Gilson R, Mercey D, et al. Hepatitis C in men who have sex with men in
London  a community survey. HIV Med 2013;14(9):578–80.
[35] Scotto R, Buonomo AR, Moriello NS, et al. Real-world efficacy and safety of pange-
notypic direct-acting antivirals against hepatitis C virus infection. Rev Recent Clin
Trials 2019;14(3):173–82.
[36] Hezode C. Treatment of hepatitis C: results in real life. Liver Int 2018;38(Suppl
1):21–7.
[37] Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virus among
gay and bisexual men: a systematic review. Sex Health 2017;14(1):28–41.
[38] Traeger MW, Schroeder SE, Wright EJ, et al. Effects of pre-exposure prophylaxis
for the prevention of HIV infection on sexual risk behavior in men who have sex
with men: a systematic review and meta-analysis. Clin Infect Dis 2018;67
(5):676–86.
[39] Basten M, Heijne JCM, Geskus R, Den Daas C, Kretzschmar M, Matser A. Sexual risk
behaviour trajectories among MSM at risk for HIV in Amsterdam, the Nether-
lands. AIDS 2018;32(9):1185–92.
[40] Prah P, Hickson F, Bonell C, et al. Men who have sex with men in Great Britain:
comparing methods and estimates from probability and convenience sample sur-
veys. Sex Transm Infect 2016;92(6):455–63.
[41] Scott N, Stoove M, Wilson DP, et al. Eliminating hepatitis C virus as a public health
threat among HIV-positive men who have sex with men: a multi-modelling
approach to understand differences in sexual risk behaviour. J Int AIDS Soc
2018;21(1).
[42] Salazar-Vizcaya L, Wandeler G, Fehr J, et al. Impact of direct-acting antivirals on
the burden of HCV infection among persons who inject drugs and men who have
sex with men in the Swiss HIV cohort study. Open Forum Infect Dis 2018;5(7)
ofy154.
[43] Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of gonorrhea and chla-
mydia following human immunodeficiency virus preexposure prophylaxis
among men who have sex with men: a modeling study. Clin Infect Dis
2017;65(5):712–8.
[44] British HIV Association. Guidelines for the Management of Hepatitis Viruses in
Adults Infected with HIV 2013. HIV Medicine 2013;14(Suppl 4):1–71.
[45] Pakianathan M, Whittaker W, Lee MJ, et al. Chemsex and new HIV diagnosis in
gay, bisexual and other men who have sex with men attending sexual health clin-
ics. HIV Med 2018;19(7):485–90.atment for elimination of hepatitis C among men who have sex with
), https://doi.org/10.1016/j.eclinm.2019.11.010
ARTICLE IN PRESS
JID: ECLINM [m5G;December 19, 2019;9:55]
L. Macgregor et al. / EClinicalMedicine 00 (2019) 100217 11[46] Vaux S, Chevaliez S, Saboni L, et al. Prevalence of hepatitis C infection, screening
and associated factors among men who have sex with men attending gay venues:
a cross-sectional survey (PREVAGAY), France, 2015. BMC Infect Dis 2019;19
(1):315.
[47] Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in
cohort studies of common outcomes. JAMA 1998;280(19):1690–1.Please cite this article as: L. Macgregor et al., Scaling up screening and tre
men in the era of HIV pre-exposure prophylaxis, EClinicalMedicine (2019[48] Johnson WD, O’Leary A, Flores SA. Per-partner condom effectiveness against HIV
for men who have sex with men. AIDS 2018;32(11):1499–505.
[49] Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual
behaviour of on-demand pre-exposure prophylaxis for HIV in men who have
sex with men: an observational cohort study. Lancet HIV 2017;4(9) e402-
e10.atment for elimination of hepatitis C among men who have sex with
), https://doi.org/10.1016/j.eclinm.2019.11.010
